ストックスクリーナーアプリを入手
1.31
0.00%
0.00
前日終値:
$1.31
開ける：
$1.32
24時間の取引高:
1,728
Relative Volume:
0.08
時価総額：
$13.53M
収益：
-
当期純損益:
$-17.93M
株価収益率:
-0.7401
EPS:
-1.77
ネットキャッシュフロー:
$-14.28M
1週間 パフォーマンス:
+6.94%
1か月 パフォーマンス:
-21.12%
6か月 パフォーマンス:
-35.78%
1年 パフォーマンス:
-8.39%
1日の値動き範囲:
$1.31
$1.3436
1週間の範囲:
$1.15
$1.47
52週間の値動き範囲:
$1.12
$3.26
Cocrystal Pharma Inc Stock (COCP) Company Profile
名前
Cocrystal Pharma Inc
セクター
電話
(786) 459-1831
住所
19805 N. CREEK PARKWAY, BOTHELL, WA
COCP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.31 | 13.53M | 0 | -17.93M | -14.28M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-08 | 開始されました | H.C. Wainwright | Buy |
Cocrystal Pharma Inc (COCP) 最新ニュース
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - TradingView
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Cocrystal Pharma Approves 2025 Equity Incentive Plan - TipRanks
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA - openPR.com
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
COCRYSTAL PHARMA Earnings Preview: Recent $COCP Insider Trading, Hedge Fund Activity, and More - Nasdaq
Q1 Earnings Forecast for COCP Issued By Zacks Small Cap - Defense World
COCP stock touches 52-week low at $1.35 amid market fluctuations By Investing.com - Investing.com South Africa
COCP stock touches 52-week low at $1.35 amid market fluctuations - Investing.com Australia
What is Zacks Small Cap’s Estimate for COCP Q3 Earnings? - Defense World
COCP: Norovirus Challenge Study Planned for 2025… - MSN
Cocrystal Pharma, Inc. SEC 10-K Report - TradingView
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - TradingView
Cocrystal Pharma Pushes Forward with Antiviral Programs Despite $17.5M Loss - Stock Titan
Influenza Pipeline: Advancing Innovation with 120+ Trailblazers Developing Transformative Therapies | DelveInsight - openPR.com
Cocrystal Pharma Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Hepatitis C Virus Infection Pipeline 2025: FDA Updates, Therapy - openPR
Cocrystal Pharma (COCP) to Release Earnings on Thursday - Defense World
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines - Investing News Network
Life Sciences Investor Forum Agenda Announced for March 13th - Morningstar
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Cocrystal Pharma to Participate in a Fireside Chat at the - GlobeNewswire
Kaltura to Host 2025 Investor Event - The Manila Times
Direct Access to Cocrystal Pharma Management: Key Details of Upcoming Zacks Analyst Forum - StockTitan
Aptorum Gr Stock Price, Quotes and Forecasts | NASDAQ:APM - Benzinga
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap - ACCESS Newswire
New Information Reveals Opportunity in Volatility -- Featured Research on Norsk Hydro, Paragon Offshore, Pure Biosciences and Cocrystal Pharma - ACCESS Newswire
Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight - The Malaysian Reserve
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch - Simply Wall St
Honeywell International Inc’s (HON) Stock: A Long-Term Performance Analysis - The News Heater
An In-Depth Look at BP plc ADR’s (BP) Stock Performance - The News Heater
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
Drugmakers prep for bird flu outbreak, despite continued low risk - PharmaVoice
Cocrystal Pharma Extends Phase 2a Influenza Drug Study Amid Lower Infection Rates, Stock Near 52-Week High - HPBL
Influenza Clinical and Non-Clinical Studies, Key Companies, - openPR
What is Northland Capmk’s Forecast for CECO FY2024 Earnings? - Defense World
HC Wainwright Forecasts Higher Earnings for Cocrystal Pharma - Defense World
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo - Research Tree
Influenza Pipeline Insights, Clinical Trials Analysis, Emerging Therapies and Companies | DelveInsight - EIN News
**Cocrystal Pharma, Inc. Presents Corporate Update to Investment Community** - Defense World
Midday Market Movers: Biggest Stock Declines of the Day – Market - HPBL
Cocrystal Pharma Engages Investors with Limited Disclosure - TipRanks
Cocrystal Pharma Reports Positive Phase 1 Results with Oral Pan-Viral Protease Inhibitor CDI-988 for Norovirus and Coronavirus Infections - Defense World
Arcturus Therapeutics launches Phase I Avian Influenza trials in US - Yahoo Finance
COCP: Phase 2a Trial of CC-42344 Extended - Smartkarma
COCP: Phase 2a Trial of CC-42344 Extended… - Zacks Small Cap Research
Cocrystal Pharma Inc (COCP) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):